Inovio () announced that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma has completed its enrollment three months ahead of schedule. The 52-patient trial is designed to evaluate Inovio’s INO-5401 T cell activating immunotherapy encoding multiple antigens expressed by GBM and INO-9012, an immune activator encoding IL-12, in combination with cemiplimab-rwlc, a PD-1 inhibitor developed by Regeneron Pharmaceuticals (REGN) in collaboration with Sanofi (SNY). This trial information will be presented at Phase I-III Trials in Progress session at the Annual Meeting of the American Association for Cancer Research being held in Atlanta. Inovio expects to report interim results from this study before the end of this year evaluating safety, immunological impact, progression-free survival and overall survival.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.